Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Clinical trial NCT02342704 · TERMINATED

Trial details

NCT number: NCT02342704
Sponsor: Biogen
Status: TERMINATED
Phase: Phase 4
Study type: INTERVENTIONAL

Relapsing-Remitting Multiple Sclerosis

Start date: 2014-11-30
Primary completion: 2016-05-18
Enrollment: 111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.